menu
    • menu

    Company profile for Cingulate Therapeutics

    NEW Drugs in Dev: 1
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Cingulate Therapeutics, LLC (CTx) is a privately held, clinical stage biopharmaceutical company focused on the development of innovative new products utilizing the Company’s proprietary Precision Timed Release™ (PTR™) drug delivery platform technology incorporating OralogiK™ that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention De...
    Cingulate Therapeutics, LLC (CTx) is a privately held, clinical stage biopharmaceutical company focused on the development of innovative new products utilizing the Company’s proprietary Precision Timed Release™ (PTR™) drug delivery platform technology incorporating OralogiK™ that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Cingulate TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1901 W 47th Place Kansas City, KS 66205
    Telephone
    Telephone
    (913) 942-2300
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://cingulatetherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/cingulate-therapeutics/?originalSubdomain=in
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cingulate hit with manufacturing-related FDA rejection
    Cingulate hit with manufacturing-related FDA rejection

    02 Jun 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/manufacturing/adhd-drug-delivery-specialist-cingulate-hit-manufacturing-related-fda-rejection

    FIERCE PHARMA
    02 Jun 2026
    Share Share
    Cingulate Reports First Quarter 2026 Financial Results
    Cingulate Reports First Quarter 2026 Financial Results

    14 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/14/3294884/0/en/cingulate-inc-reports-first-quarter-2026-financial-results-and-provides-an-update-of-commercial-readiness-efforts-on-track-for-lead-adhd-asset-ctx-1301.html

    GLOBENEWSWIRE
    14 May 2026
    Share Share
    Cingulate Unveils 2025 Financials And Operational Highlights
    Cingulate Unveils 2025 Financials And Operational Highlights

    18 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/18/3258107/0/en/Cingulate-Inc-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Operational-Highlights.html

    GLOBENEWSWIRE
    18 Mar 2026
    Share Share
    Cingulate Closes $12M At-The-Market Private Placement On Nasdaq
    Cingulate Closes $12M At-The-Market Private Placement On Nasdaq

    17 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/17/3239219/0/en/Cingulate-Announces-the-Closing-of-a-12-Million-Private-Placement-Priced-At-the-Market-Under-Nasdaq-Rules.html

    GLOBENEWSWIRE
    17 Feb 2026
    Share Share
    Cingulate Reports Q3 2025 Financials And Corporate Update
    Cingulate Reports Q3 2025 Financials And Corporate Update

    13 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/13/3187260/0/en/Cingulate-Inc-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    13 Nov 2025
    Share Share
    Cingulate Appoints Bryan Downey Chief Commercial Officer
    Cingulate Appoints Bryan Downey Chief Commercial Officer

    10 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/10/3184474/0/en/Cingulate-Names-Industry-Veteran-Bryan-Downey-Chief-Commercial-Officer-to-Lead-Launch-Preparation-for-CTx-1301.html

    GLOBENEWSWIRE
    10 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search